Literature DB >> 395119

Short in vitro half-life of thymopoietin32--36 pentapeptide in human plasma.

J P Tischio, J E Patrick, H S Weintraub, M Chasin, G Goldstein.   

Abstract

Thymopoietin32--36 (TP5) is a synthetic pentapeptide that has the biological activity of its parent molecule, the 49 amino acid thymic hormone thymopoietin. Tritiated thymopoietin32--36 (3 /-TP5) was prepared by reductive tritiation of dibromotyrosyl-TP5. The stability of 3 H-TP5 in human plasma was studied by analyzing samples by thin-layer chromatography at different time points and quantitating the radioactivity associated with TP5 (Arg-Lys-Asp-Val-Tyr) and its tyrosyl-containing breakdown products (Lys-Asp-Val-Tyr, Asp-Val-Tyr, Val-Tyr, Tyr). In plasma (but not in saline) the pentapeptide was rapidly degraded (apparent t1/2 approximately 30 seconds) with the corresponding appearance of radioactivity associated with the other tyrosyl-containing reference compounds. These data imply that the pentapeptide, which is active in vivo, may rapidly trigger changes in responsive cells; sustained circulating levels may not be required for activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 395119     DOI: 10.1111/j.1399-3011.1979.tb01959.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  11 in total

1.  Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.

Authors:  Yan-Zhen Li; Xun Sun; Tao Gong; Jie Liu; Jiao Zuo; Zhi-Rong Zhang
Journal:  Pharm Res       Date:  2010-07-13       Impact factor: 4.200

2.  Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.

Authors:  Ting Zhang; Xian-Yan Qin; Xi Cao; Wen-Hao Li; Tao Gong; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

3.  Thymopentin: stability considerations and potency by various routes of administration.

Authors:  T K Audhya; G Goldstein
Journal:  Surv Immunol Res       Date:  1985

4.  Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis.

Authors:  M Malaise; P Franchimont; C Hauwaert; B Danneskiold-Samsoe; D Gross; H Gerber; H Gerschpacher; K Bolla
Journal:  Surv Immunol Res       Date:  1985

Review 5.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

6.  Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis.

Authors:  E M Veys; E C Huskisson; M Rosenthal; T L Vischer; H Mielants; P A Thrower; J Scott; H Ott; H Scheijgrond; J Symoens
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

7.  Implantable sandwich PHBHHx film for burst-free controlled delivery of thymopentin peptide.

Authors:  Ke Peng; Chengyu Wu; Guoxu Wei; Jinghui Jiang; Zhirong Zhang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2018-04-07       Impact factor: 11.413

8.  Preparation, intestinal segment stability, and mucoadhesion properties of novel thymopentin-loaded chitosan derivatives coated with poly (n-butyl) cyanoacrylate nanoparticles.

Authors:  Ying Xu; Shengzhe Lu; Qi Liu; Yun Hong; Bohui Xu; Qineng Ping; Xuefeng Jin; Yan Shen; Thomas J Webster; Yuefeng Rao
Journal:  Int J Nanomedicine       Date:  2019-03-04

9.  Thymosin alpha 1: biological activities, applications and genetic engineering production.

Authors:  Juan Li; Chun Hui Liu; Feng Shan Wang
Journal:  Peptides       Date:  2010-08-10       Impact factor: 3.750

10.  A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Dayong Si; James N Petitte; Baseer Ahmad; Manyi Zhang
Journal:  Int J Mol Sci       Date:  2019-08-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.